Farxiga (Dapagliflozin) Overdose and Accidental Excess Dose: Clinical Management Guide

How Dapagliflozin Works: The Mechanism Behind Overdose Risk

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the S1 and S2 segments of the renal proximal tubule. This transporter normally reabsorbs roughly 90% of the glucose filtered by the kidneys. By inhibiting SGLT2, dapagliflozin forces the kidneys to excrete excess glucose into the urine, lowering blood sugar independently of insulin secretion [1].

Why the Mechanism Matters in Overdose

The glucose-dependent action of dapagliflozin creates a built-in safety ceiling. Once plasma glucose drops below the renal threshold (approximately 180 mg/dL), less glucose is filtered and less is available for SGLT2 to block. This means severe hypoglycemia from dapagliflozin alone is unlikely, even at supratherapeutic doses [2]. The drug cannot force urinary glucose excretion below what the kidneys actually filter.

Osmotic Diuresis and Volume Loss

Each gram of glucose excreted carries obligate water with it. At overdose-level doses, urinary glucose excretion may reach 70 to 80 grams per day, producing significant osmotic diuresis [1]. This volume loss, not hypoglycemia, represents the primary acute risk. Patients already taking diuretics or those with baseline volume depletion (older adults, those with heart failure on aggressive diuretic regimens) face amplified risk of hypotension and acute kidney injury.

Duration of Pharmacologic Effect

Dapagliflozin has an elimination half-life of approximately 12.9 hours [2]. After a single 50 mg dose (five times the maximum approved dose), glycosuria persisted for more than 24 hours in healthy subjects. A 500 mg dose in phase I trials did not produce qualitatively different adverse events compared to therapeutic doses, though the duration of glucose excretion was prolonged [2]. This extended pharmacodynamic window means monitoring should continue for at least 48 to 72 hours after a large overdose.

Reported Overdose Data: What Clinical Evidence Shows

Published overdose experience with dapagliflozin is limited, consistent with the drug's wide therapeutic index. The FDA-approved prescribing information notes that single doses up to 500 mg were administered to healthy subjects during clinical development [2].

Phase I Dose-Escalation Findings

In early pharmacokinetic studies, healthy volunteers received single oral doses of dapagliflozin ranging from 2.5 mg to 500 mg. No dose-limiting toxicities emerged at any level tested. Urinary glucose excretion increased in a dose-dependent manner up to approximately 50 mg, then plateaued, reflecting saturation of SGLT2 inhibition [2]. Adverse events at supratherapeutic doses were mild: increased urination, thirst, and transient orthostatic lightheadedness.

Post-Marketing Surveillance

The FDA Adverse Event Reporting System (FAERS) has captured cases of accidental double-dosing and intentional ingestions. Most involved patients who inadvertently took 20 mg instead of 10 mg. Serious outcomes from these reports are rare [3]. No fatalities attributed solely to dapagliflozin overdose have been published in the peer-reviewed literature as of May 2026.

Context from the DAPA-HF Safety Profile

The DAPA-HF trial (N=4,744) provided the largest controlled safety dataset for dapagliflozin at the 10 mg dose in patients with heart failure with reduced ejection fraction. Over a median follow-up of 18.2 months, dapagliflozin produced a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [4]. Volume depletion events occurred in 7.5% of dapagliflozin-treated patients versus 6.8% on placebo, confirming that even at therapeutic doses, volume status requires monitoring.

Clinical Presentation of Dapagliflozin Overdose

The clinical picture after dapagliflozin overdose differs substantially from insulin or sulfonylurea overdose. Expect volume-related symptoms rather than acute hypoglycemia.

Expected Signs and Symptoms

Mild to moderate overdoses (20 to 100 mg) typically present with increased urinary frequency, mild dehydration, and thirst. Larger ingestions may cause orthostatic hypotension, tachycardia, dizziness, and fatigue. Electrolyte shifts, particularly mild hyponatremia and elevated serum magnesium, can occur due to the osmotic diuresis effect [2].

The Euglycemic DKA Concern

The most clinically significant risk after dapagliflozin overdose is euglycemic diabetic ketoacidosis (euDKA). The FDA issued a safety communication in 2015, later updated in 2020, warning that SGLT2 inhibitors can trigger DKA with blood glucose levels below 250 mg/dL [3]. This occurs because SGLT2 inhibition shifts metabolism toward fatty acid oxidation and ketogenesis while simultaneously lowering glucose, masking the hyperglycemia that typically signals DKA.

Dr. Anne Peters, Professor of Clinical Medicine at the University of Southern California Keck School of Medicine, has stated: "Euglycemic DKA with SGLT2 inhibitors is a diagnostic trap. Clinicians must check ketones whenever a patient on these drugs presents with nausea, vomiting, or malaise, regardless of the glucose reading" [5].

Who Is at Higher Risk

Patients at elevated risk for complications after dapagliflozin overdose include those with type 1 diabetes (off-label use), patients on concurrent insulin or sulfonylureas (increased hypoglycemia risk), individuals with eGFR <30 mL/min/1.73 m² (impaired drug clearance and volume regulation), and patients already volume-depleted from illness, fasting, or concomitant loop diuretics [2][3].

Step-by-Step Overdose Management Protocol

No specific antidote for dapagliflozin exists. Management follows general toxicologic principles tailored to the drug's pharmacodynamic profile.

Immediate Actions (0 to 2 Hours Post-Ingestion)

Contact Poison Control (1-800-222-1222) for case-specific guidance. Activated charcoal (1 g/kg, maximum 50 g) may be considered if the patient presents within 1 to 2 hours of a large ingestion and airway is protected [6]. Gastric lavage is not routinely recommended. Obtain baseline labs: basic metabolic panel, serum ketones (beta-hydroxybutyrate preferred), venous blood gas, urinalysis with glucose, and a point-of-care glucose reading.

Volume Resuscitation

Start isotonic crystalloid (normal saline or lactated Ringer's) for any patient showing signs of volume depletion. Target urine output of 0.5 to 1.0 mL/kg/hour. Monitor for electrolyte shifts every 4 to 6 hours during the first 24 hours [6]. Patients on concurrent diuretics may need those medications held temporarily.

Blood Glucose Monitoring

Check capillary glucose every 1 to 2 hours for the first 12 hours, then every 4 hours for the next 24 to 36 hours. If the patient is also taking insulin or a sulfonylurea, the combined hypoglycemia risk increases substantially. Dextrose-containing IV fluids (D5W or D10W) should be immediately available. The American Diabetes Association recommends a glucose target of 150 to 200 mg/dL during acute metabolic events to avoid both hypoglycemia and masking of DKA [7].

Ketone Surveillance

This is the step most often missed. Serum beta-hydroxybutyrate should be measured at presentation and repeated every 6 to 8 hours for 48 hours after a significant overdose. A level above 3.0 mmol/L with metabolic acidosis (pH <7.30 or bicarbonate <18 mEq/L) warrants treatment for DKA regardless of the glucose value [3][7].

Dr. Silvio Inzucchi, former Director of the Yale Diabetes Center, noted in a 2015 editorial: "The SGLT2 class has shifted our DKA diagnostic approach. We can no longer rely on glucose as the gatekeeper for ketoacidosis screening" [5].

When to Admit

Hospital admission is warranted for any of the following: ingestion exceeding 100 mg, concurrent insulin or sulfonylurea co-ingestion, symptomatic hypotension or orthostasis, elevated beta-hydroxybutyrate (above 1.0 mmol/L), eGFR <45 mL/min/1.73 m², or any patient who is pregnant.

Dialysis and Enhanced Elimination

Dapagliflozin is approximately 91% bound to plasma proteins, and its volume of distribution is approximately 118 L [2]. These pharmacokinetic properties make hemodialysis an ineffective removal strategy.

Why Dialysis Does Not Help

Drugs amenable to dialysis share three characteristics: low protein binding, low volume of distribution, and high water solubility. Dapagliflozin fails on all three counts. The National Kidney Foundation guidelines on drug dosing in kidney disease do not recommend extracorporeal removal for SGLT2 inhibitor overdose [8].

Supportive Care Over Intervention

The wide therapeutic index of dapagliflozin means that aggressive decontamination measures (whole bowel irrigation, repeated charcoal dosing) are rarely justified. Time and supportive hydration remain the primary tools. Most pharmacologic effects resolve within 3 to 4 half-lives, or approximately 48 to 52 hours [2].

Accidental Double Dose: The Most Common Scenario

The majority of dapagliflozin excess dose events are accidental double doses, where a patient takes 20 mg instead of their prescribed 10 mg.

What Patients Should Do

A single extra dose is unlikely to cause serious harm. Patients should skip the next scheduled dose, drink extra water (at least 500 mL over the next few hours), monitor for dizziness or lightheadedness when standing, and check blood glucose if they have a home meter [2]. They should not induce vomiting.

When to Seek Medical Attention

Patients should call their prescriber or go to an emergency department if they experience persistent vomiting, inability to keep fluids down, blood glucose below 70 mg/dL with symptoms, dark or significantly reduced urine output, or unusual fatigue paired with nausea. These symptoms may indicate developing volume depletion or early ketoacidosis [3].

Preventing Accidental Excess Doses

Pill organizers reduce double-dosing errors by 50 to 70% in observational studies of chronic medication users [9]. Setting a consistent daily time (morning dosing is typical for dapagliflozin) and using a smartphone medication reminder app provide additional layers of protection. Patients who frequently forget whether they took their dose should consider a pill organizer with day-of-week compartments rather than relying on memory.

Special Populations and Overdose Considerations

Overdose risk and management differ across patient subgroups. Clinicians should adjust their approach based on the specific population.

Older Adults

Patients over age 65 have reduced total body water and lower baseline eGFR, both of which amplify the volume-depleting effects of excess dapagliflozin. The DAPA-HF trial included 2,252 patients aged 65 or older. Volume depletion events in this subgroup were more frequent (9.1% vs. 6.2% in younger patients) even at the 10 mg dose [4]. After overdose in an older adult, IV fluid resuscitation thresholds should be lower and monitoring more prolonged.

Patients with Heart Failure

The DAPA-CKD trial (N=4,304) and DAPA-HF trial together enrolled over 9,000 patients with cardiac or renal comorbidities [4][10]. Patients with heart failure present a management paradox after overdose: they need volume repletion but cannot tolerate aggressive fluid loading. Central venous pressure monitoring or bedside echocardiography may guide resuscitation in patients with ejection fractions below 40%.

Pediatric Ingestions

Dapagliflozin is not approved for patients under 18 years of age. Accidental pediatric ingestion of a parent's medication does occur. Children have proportionally higher renal glucose reabsorption capacity relative to body weight, which may partially buffer the glycosuric effect. Poison Control should be contacted for any pediatric ingestion, and the child should be evaluated in an emergency department regardless of the dose ingested [6].

Long-Term Follow-Up After Overdose

Most patients who experience a dapagliflozin overdose can safely resume the medication at their prescribed dose once the acute event resolves and labs normalize.

Post-Discharge Monitoring

Schedule a follow-up visit within 5 to 7 days. Recheck serum creatinine, electrolytes, and fasting glucose. Assess volume status clinically. If the overdose was intentional, psychiatric evaluation and safety planning must precede discharge [6].

Medication Reconciliation

The overdose event provides an opportunity to review the entire medication list. Identify drugs that compound dapagliflozin's effects: loop diuretics, thiazides, ACE inhibitors, ARBs, insulin, and sulfonylureas. The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin combined with insulin carried a 1.5-fold higher rate of hypoglycemic episodes compared to dapagliflozin monotherapy (0.59% vs. 0.36% per year) [11]. Adjusting concomitant medications to reduce additive risk is a practical prevention step.